Etamzilat instructions for use for animals. Etamzilat - instructions for use, indications, side effects, analogues and price. Injections during menstruation

INSTRUCTIONS
on the medical use of the drug

Registration number:

P N013946/02

Trade name of the drug:

Dicynon

International non-proprietary name:

etamsylate

Dosage form:

Solution for intravenous and intramuscular administration.

Compound:

Each 2 ml (1 ampoule) solution for intravenous and intramuscular administration contains:
Active substances: etamsylate 250 mg.
Excipients: sodium disulfite 0.84 mg, water for injection up to 2 ml, sodium bicarbonate for pH correction.

Description:
Colorless transparent solution.

Pharmacotherapeutic group:

hemostatic agent.

CodeATX: B02BX01

Pharmacological properties:

Pharmacodynamics
Etamzilat is a hemostatic, antihemorrhagic and angioprotective agent, normalizes the permeability of the vascular wall, improves microcirculation. Stimulates the formation of platelets and their exit from the bone marrow. It increases platelet adhesion, stabilizes capillary walls, thus reducing their permeability, inhibits the synthesis of prostaglandins, which cause platelet disaggregation, vasodilation and increase capillary permeability, which reduces bleeding time and reduces blood loss. Increases the rate of formation of the primary thrombus and enhances its retraction, has virtually no effect on the concentration of fibrinogen in the blood plasma and prothrombin time.
With repeated use, thrombus formation increases.
Etamzilat practically does not affect the composition of peripheral blood, its proteins and lipoproteins. The erythrocyte sedimentation rate may decrease slightly. Reduces the release of fluid and diapedesis of blood cells from the vascular bed, improves microcirculation. Does not have a vasoconstrictive effect.
Possessing anti-hyaluronidase activity and stabilizing ascorbic acid, it prevents destruction and promotes the formation of mucopolysaccharides with a large molecular weight in the capillary wall, increases the resistance of capillaries, reduces their "fragility", and normalizes permeability during pathological processes. This angioprotective effect is manifested in the treatment of various diseases associated with primary and secondary disorders of the microcirculation process.

Pharmacokinetics
The hemostatic effect with intravenous application of etamsylate solution occurs after 5-15 minutes, the maximum effect - after 1-2 hours. The action lasts for 4-6 hours, then gradually weakens within 24 hours. When administered intramuscularly, the hemostatic effect occurs in 30-60 minutes.
After intravenous / intramuscular administration of 500 mg of etamsylate, the maximum plasma concentration is reached after 10 minutes and is 30-50 μg / ml.
Almost completely penetrates the placental barrier. It is not known whether etamsylate passes into breast milk.
About 90% of etamsylate binds to plasma proteins.
Etamsylate is slightly metabolized.
About 80% of the administered dose is excreted through the kidneys unchanged. The plasma half-life after intravenous administration is about 2 hours. About 85% of the administered dose of etamsylate is excreted within 24 hours.
Clinical studies on the use of etamsylate in patients with impaired liver and / or kidney function have not been conducted.

Indications for use

Prevention and treatment of capillary bleeding of various etiologies:

• before, during and after surgical interventions on all well-vascularized tissues in dental, otorhinolaryngological, gynecological, urological, ophthalmic practice, obstetrics and plastic surgery;
• hematuria, metrorrhagia, primary menorrhagia, menorrhagia in women with intrauterine contraceptives, epistaxis, bleeding gums;
• diabetic microangiopathy (hemorrhagic diabetic retinopathy, recurrent retinal hemorrhage, hemophthalmos);
• intracranial hemorrhages in newborns and premature babies.

Contraindications

• Hypersensitivity to the components of the drug.
• Bronchial asthma, confirmed hypersensitivity to sodium sulfite.
• Acute porphyria.
• Hemoblastosis in children (lymphoblastic and myeloid leukemia, osteosarcoma).
• Thromboembolism, thrombosis.

Carefully
Thrombosis, thromboembolism in history; bleeding due to an overdose of anticoagulants.

Use during pregnancy and lactation
There are no clinical data on the possibility of using Dicinon in pregnant women. The use of Dicinon during pregnancy is possible only if the intended benefit to the mother outweighs the potential risk to the fetus.
When prescribing the drug during lactation, the issue of stopping breastfeeding should be resolved.

Dosage and administration

Intramuscularly, intravenously.
The optimal daily dose of etamsylate for adults is 10-20 mg / kg of body weight per day, divided into 3-4 doses, as an intramuscular or slow intravenous injection.
Adults
During surgical interventions, 250-500 mg (1-2 ampoules) are administered intravenously or intramuscularly prophylactically or intramuscularly 1 hour before surgery. During the operation, 250-500 mg (1-2 ampoules) of etamsylate are administered intravenously, if necessary, the administration of this dose can be repeated again. After surgery, 250-500 mg (1-2 ampoules) are administered every 4-6 hours until the risk of bleeding disappears.
To stop bleeding, 250-500 mg (1-2 ampoules) are administered intravenously or intramuscularly, after which 250 mg every 4-6 hours for 5-10 days.
In the treatment of metro- and menorrhagia, the drug is used in a single dose of 250 mg intravenously or intramuscularly every 6-8 hours for 5-10 days.
In diabetic microangiopathy, the drug is administered subconjunctival or retrobulbarno at a dose of 125 mg (1/2 ampoule). The drug Dicinon can be applied topically (for example, in the case of a skin graft, after tooth extraction, etc.): a sterile swab or napkin is impregnated with a solution and applied to the wound.
children: adult dose should be reduced by 50%.
In neonatology the drug Dicinon is used intramuscularly at a dose of 10 mg per kg of body weight (0.1 ml = 12.5 mg). Treatment should begin within the first 2 hours after birth, then every 6 hours for 4 days.
If Dicinon is mixed with a 0.9% sodium chloride solution, it should be applied immediately. Side effect

Side effect

According to the World Health Organization (WHO), undesirable effects are classified according to their frequency of development as follows: often (> 1/100,<1/10), нечасто (>1/1000, <1/100), редко (>1/10000, <1/1000) и очень редко (<1/10000), включая отдельные сообщения.
From the digestive system
often: nausea, heaviness in the epigastric region.
From the skin and subcutaneous tissues
often: skin rash;
frequency unknown: flushing of the skin of the face.
From the side of the nervous system
often: headache;
frequency unknown: dizziness, paresthesia of the lower extremities.
From the side of the cardiovascular system
very rarely: thromboembolism, pronounced decrease in blood pressure.
From the blood and lymphatic system
very rarely: agranulocytosis, neutropenia, thrombocytopenia.
From the side of the musculoskeletal system
rarely: arthralgia.
From the side of the immune system
very rarely: allergic reactions.
Other
often: asthenia;
very rarely: fever.

Overdose

To date, no cases of overdose have been described.
If an overdose has occurred, symptomatic therapy should be started.

Interaction with other drugs
Pharmaceutically incompatible (in one syringe) with other drugs.
Dicinon injection solution is incompatible with sodium bicarbonate injection and sodium lactate solution. Administration at a dose of 10 mg/kg 1 hour before dextrans (average molecular weight 30-40 thousand Da) prevents their antiplatelet action.
Action: the introduction after does not have a hemostatic effect.
Perhaps a combination with aminocaproic acid and menadione sodium bisulfite.
Thiamine (vitamin B1) is inactivated by sodium sulfite, which is part of the drug Dicinon.

special instructions

For use in hospitals and clinics only.
Other causes of bleeding should be ruled out before starting treatment. If the color of the solution appears, it should not be used.
The drug is not effective in patients with thrombocytopenia. In hemorrhagic complications associated with an overdose of anticoagulants, it is recommended to use specific antidotes.
The use of the drug Dicinon in patients with impaired parameters of the blood coagulation system is possible, but it should be supplemented by the administration of drugs that eliminate the identified deficiency or defect of blood coagulation factors. Due to the increased risk of hypotension (pronounced decrease in blood pressure) with parenteral administration of Dicinon, caution should be exercised in patients with unstable blood pressure or a tendency to hypotension.
Solution for injection Dicinon in its composition contains sodium sulfite as an antioxidant, which can cause allergic reactions, nausea, diarrhea in patients with hypersensitivity to it. Allergic reactions can be severe and manifest as anaphylactic shock and/or life-threatening asthma attacks. The frequency of occurrence is unknown, however, such a pathological reaction is observed more often in patients with bronchial asthma. If such an allergic reaction occurs, the use of the drug Dicinon should be immediately discontinued. Clinical studies on the use of the drug Dicinon in patients with impaired liver and kidney function have not been conducted, therefore, caution should be exercised when using etamsylate in this category of patients.
No special precautions are required for the destruction of unused medicinal product.

Influence on the ability to concentrate
No special precautions required.

Release form

Solution for intravenous and intramuscular injection 125 mg / ml, 2 ml of the drug in an ampoule of colorless neutral glass with a red break point. On the top of the ampoule is a blue ring.
5 or 10 ampoules in a blister, 2 or 5 blisters in a cardboard box along with instructions for use.

Storage conditions

Store at a temperature not exceeding 25°C, protected from light.
Keep out of the reach of children.

Best before date

5 years.
Do not use after the expiration date.

Terms of dispensing from pharmacies

On prescription.

Manufacturer

Lek d.d., Verovshkova 57, 1526 Ljubljana, Slovenia.

Submit consumer complaints
ZAO "Sandoz"
123317, Moscow, Presnenskaya emb., 8, building 1

Etamzilat belongs to the pharmacological group of hemostatic, coagulant drugs. The drug has a pronounced hemostatic effect. It has proaggregant, hemostatic, and angioprotective therapeutic effects. Etamzilat is used in the field of modern medicine for the treatment and prevention of capillary bleeding. It is prescribed for patients suffering from thrombocytopenia, diabetic angiopathy, hemorrhagic diathesis. Etamzilat is used as a prophylactic during various types of surgical interventions.

1. Pharmacological action

A drug that stops bleeding, improves blood circulation in the capillaries and normalizes the permeability of the wall of blood vessels.

The therapeutic effect occurs after 15 minutes and lasts up to six hours.

2. indications for use

• Prevention of capillary bleeding;
• Emergency stop of internal bleeding;
• Hemorrhagic diathesis;
• Reducing blood loss during surgical interventions of any nature.

3. How to use

Recommended dosage of Etamzilat:

• for pediatric patients: 15 mg of the drug per kg of body weight per day, dividing the amount received into three doses;
• in the form of tablets for adult patients: 250-500 mg of the drug up to four times a day;
• in the form of intravenous or intramuscular injections for adult patients: 125-250 mg of the drug up to four times a day.

Application Features:
For external use of Etamzilat on the wound, it is necessary to apply a swab dipped in a preparation in the form of a solution for injection.

4. Side effects

• Central nervous system: dizziness, headaches, involuntary muscle contractions of the lower limb;
• Cardiovascular system: reddening of the face, lowering the level of systolic blood pressure;
• Digestive system: feeling of heaviness in the stomach, heartburn.

5. Contraindications

• The presence of thrombosis in the vessels;
• Hypersensitivity to Etamsylat or its components;
• Blockage of blood vessels by a thrombus;
• Individual intolerance to Etamzilat or its components;
• Simultaneous use of Etamzilat with any drugs.

6. During pregnancy and lactation

Use Etamzilat during pregnancy not recommended.

During lactation, the use of Etamzilat is not recommended.

7. Interaction with other drugs

Etamzilat is incompatible with any drugs.

8. Overdose

An overdose of etamzilat has not been described.

9. Release form

Solution for injection in ampoules, 250 mg / 2 ml - amp. 5, 10 or 50 pcs; 125 mg/ml - 2 ml amp. 10 pieces.
Tablets, 250 mg - 10, 50 and 100 pcs.
Solution, 250 mg / 2 ml - amp. 5 or 10 pcs; 125 mg/ml - 2 ml amp. 10 pieces

10. Storage conditions

Etamzilat should be stored in a dry, dark place.

11. Composition

One tablet of the drug:
250 mg Etamsylate (2,5-dihydroxybenzenesulfonic acid with diethylamine).

12. Terms of dispensing from pharmacies

The drug is released according to the prescription of the attending physician.

Found an error? Select it and press Ctrl + Enter

* Instructions for medical use for the drug Etamzilat published in free translation. THERE ARE CONTRAINDICATIONS. BEFORE USE, IT IS NECESSARY TO CONSULT WITH A SPECIALIST

Etamzilat

International non-proprietary name

Etamzilat

Dosage form

Solution for injection 12.5%, 2 ml

Compound

One ampoule contains

active substance- etamsylate - 250.0 mg,

Excipients: sodium metabisulfite, sodium sulfite anhydrous, water for injection.

Description

Clear, colorless or slightly colored liquid.

Pharmacotherapeutic group

Hemostatics. Vitamin K and other hemostatics. Other systemic hemostatics. Etamzilat.

ATX code B02BX01

Pharmacological properties

Pharmacokinetics

After intravenous administration of 500 mg of etamsylate, the maximum plasma concentration is reached after 10 minutes; the plasma half-life is approximately 1.9 hours. About 85% of the dose taken is excreted in the urine during the first 24 hours.

The degree of binding to plasma proteins is approximately 95%. The plasma half-life is approximately 3.7 hours. About 72% of the dose taken is excreted unchanged during the first 24 hours in the urine. Etamsylat crosses the placental barrier. Maternal and cord blood contain similar concentrations of etamsylate. It is not known whether etamsylate passes into breast milk.

Pharmacokinetics in patients with hepatic and renal insufficiency has not been studied.

Pharmacodynamics

Etamzilat is a synthetic hemostatic and angioprotective drug used as a primary hemostatic agent, which is due to increased interaction between the endothelium and platelets, which promotes adhesion and aggregation of platelets, and ultimately leads to a stop or decrease in bleeding. The hemostatic effect of etamsylate develops when administered intravenously after 5-15 minutes, the maximum effect occurs after 1-2 hours, the effect lasts 4-6 hours or more. With intramuscular injection, the effect occurs somewhat more slowly. When taken orally, the maximum effect is noted after 3 hours. Etamzilat stimulates the formation of platelets and their release from the bone marrow, accelerates the formation of tissue thromboplastin, increases the rate of formation of the primary thrombus at the site of injury and enhances its retraction. Etamzilat enhances the formation of high molecular weight mucopolysaccharides in the capillary wall, increases the resistance of capillaries, normalizes their permeability in pathological processes and improves microcirculation. Against the background of treatment with Etamzilat, pathologically altered hemostasis parameters are restored. Etamzilat does not have a vasoconstrictive effect, does not affect fibrinolysis and does not change plasma coagulation factors.

Indications for use

Prevention and stopping of capillary and parenchymal bleeding of various etiology and localization in otorhinolaryngology, microsurgery, ophthalmology, dentistry, urology, surgery and gynecology.

Hematuria

Intracranial hemorrhage (including in newborns and premature babies)

Nosebleeds due to arterial hypertension

Bleeding due to medication

Hemorrhagic diathesis (including Werlhof disease, Willebrand-Jurgens disease, thrombocytopathy)

Dosage and administration

adults

Before surgery: 1-2 ampoules (250 - 500 mg) intravenously or intramuscularly 1 hour before surgery.

During the operation(if necessary): 1-2 ampoules (250 - 500 mg) intravenously.

After operation(prophylactically): if there is a risk of bleeding, after surgery, 1-2 ampoules (250-500 mg) should be administered prophylactically intravenously or intramuscularly every 4-6 hours.

Emergency cases, according to the severity of the case: 1-2 ampoules intravenously or intramuscularly every 4-6 hours for as long as there is a risk of bleeding.

Local treatment: moisten the swab with the contents of the ampoule and apply to the site of bleeding, or the tooth socket after tooth extraction. If necessary, the application of a tampon moistened with the contents of the ampoule can be repeated, or combined with oral or parenteral administration of the drug.

Children: the daily dose is 10-15 mg/kg of body weight, divided into 3-4 doses.

Neonatology: Etamsylate should be administered intramuscularly or intravenously at 10 mg/kg body weight (0.1 ml = 12.5 mg), within 2 hours after birth, and then every 6 hours for 4 days.

Special Populations:

The use of the drug in the form of a solution for injection in patients with hepatic or renal insufficiency should be carried out under the strict supervision of a physician.

Side effects

Adverse reactions are listed by MedDRA classification by organ class and frequency as follows:

Very common (≥ 1/10)

Often (≥ 1/100,<1/10)

Uncommon (≥ 1/1000,<1/100)

Rare (≥ 1/10000 to<1/1000)

Very rarely (<1/10000), не известно (из имеющихся данных не могут быть оценены)

From the digestive system

Often

Nausea, abdominal pain, abdominal discomfort, diarrhea

From the skin and subcutaneous tissue

Often

Skin rash

From the side of the nervous system

Often

Headache, vascular disorders

Very rarely

Thromboembolism, hypotension

From the blood and lymphatic system

Very rarely

- agranulocytosis, neutropenia, thrombocytopenia

From the side of the musculoskeletal system

Rarely

Arthralgia

From the side of the immune system

Very rarely

Allergic reactions (anaphylactic shock, life-threatening asthma attacks)

Often

Asthenia

Very rarely

Fever

These side effects are usually reversible and disappear after treatment.

In the event of adverse skin reactions or fever, discontinue treatment and inform your doctor as these may be the first signs of hypersensitivity.

Contraindications

Hypersensitivity to any component of the drug

Acute porphyria

Bronchial asthma

Hemoblastosis in children (lymphoblastic and myeloid leukemia, osteosarcoma)

Thrombosis, thromboembolism

Drug Interactions

Introduction at a dose of 10 mg/kg of body weight 1 hour before the administration of dextrans (average molecular weight 30-40 thousand Da) prevents their antiaggregant effect. The introduction of Etamzilat after the introduction of dextrans does not have a hemostatic effect.

Perhaps a combination with aminocaproic acid and menadione sodium bisulfite.

Pharmaceutically incompatible (in one syringe) with other drugs.

If simultaneous administration with dextran is necessary, the etamsylate solution should be administered first.

According to studies, when administered intravenously, Etamzilat can affect the blood levels of creatinine, lactate, triglycerides, uric acid and cholesterol, determined by the enzymatic method, for up to 12 hours. During treatment with Etamzilat, it is recommended that samples (eg, blood) be taken before the first administration of the drug in order to minimize the impact on laboratory results.

special instructions

Caution is required (despite the absence of thrombus induction) when prescribing Etamzilat to patients with a history of thrombosis or thromboembolism.

In hemorrhagic complications associated with an overdose of anticoagulants, it is recommended to use specific antidotes. The use of Etamzilat in patients with impaired parameters of the blood coagulation system is possible, but it should be supplemented by the administration of drugs that eliminate the identified deficiency or defect of the coagulation system factors.

Before starting treatment, it must be borne in mind that the drug is ineffective in patients with thrombocytopenia.

Since parenteral administration of the drug Etamzilat can cause a decrease in blood pressure, careful monitoring of patients suffering from changes in blood pressure or hypotension should be carried out.

Etamzilat contains sulfites, which is why it is also necessary to be careful when administering it to patients with allergies.

In the event of an allergic reaction, treatment with the drug should be discontinued immediately.

Pregnancy and lactation.

Application during pregnancy is possible only in cases where the potential benefit of therapy for the mother outweighs the possible risk to the fetus. If necessary, the appointment of the drug during lactation should decide on the termination of breastfeeding.

Features of the influence of the drug on the ability to drive a vehicle or potentially dangerous mechanisms

There is no data on the effect of the drug on the ability to manage transport and other mechanisms that require concentration.

Overdose

Cases of overdose have not been identified. In case of overdose, treatment is symptomatic.

Release form and packaging

2.0 ml of the drug is poured into neutral glass ampoules or sterile syringe-filled ampoules, or imported.

Each ampoule is labeled with label paper or writing paper, or the text is applied directly to the ampoule with gravure printing ink for glass products.

5 ampoules are packed in a blister pack of film

PVC and aluminum foil

2 or 10 contour packs, together with the approved instructions for medical use in the state and Russian languages, are placed in a cardboard pack. An ampoule scarifier is put into each pack. When packing ampoules with notches, rings and dots, scarifiers are not included.

It is allowed to place blister packs (without investing in a pack of cardboard) into cardboard boxes. According to the number of packages, each box contains instructions for medical use in the state and Russian languages.

Storage conditions

Store in a dry, dark place at a temperature not exceeding 25°C.

Keep out of the reach of children!

Shelf life

Do not use after the expiration date.

Terms of dispensing from pharmacies

On prescription

Manufacturer

JSC "Khimfarm", Kazakhstan,

Shymkent, st. Rashidova, 81

Registration certificate holder

JSC Chimpharm, Kazakhstan

Address of the organization accepting claims from consumers on the quality of products (goods) on the territory of the Republic of Kazakhstan

JSC Chimpharm, Kazakhstan

Shymkent st. Rashidova, 81

Fax number +7 7252 (561342)

Name, address of the organization on the territory of the Republic of Kazakhstan responsible for post-registration surveillance of the safety of the medicinal product

JSC "Khimfarm", Republic of Kazakhstan, Shymkent, st. Rashidova, 81,

Phone number +7 7252 (561342)

Fax number +7 7252 (561342)

E-mail address [email protected]

Etamzilat is a drug (solution) that corresponds to the group of hemostatic drugs. In the instructions for use, the following features of the drug are distinguished:

• Sold by prescription only
• In childhood: contraindicated

Package

Compound

One tablet of the drug contains sodium etamsylate 0.25 g and excipients.

Solution for injection contains 0.125 etamsylate per 1 ml + excipients (water for injection, sodium disulfite, disodium edetate, anhydrous sodium sulfite).

Release form

Convex round tablets, packs of 50 and 100 pieces.

Solution for injection in ampoules, colorless, clear or slightly yellow. Packs of 1, 2 or 10 ampoules.

pharmachologic effect

Angioprotector, hemostatic.

Pharmacodynamics and pharmacokinetics

The drug activates the formation of thromboplastin and mucopolysaccharides, thereby exhibiting hemostatic activity.

It normalizes the rate of blood clotting, increases the stability and elasticity of capillary walls, improves microcirculation processes even in the smallest vessels and capillaries.

It is noteworthy that the drug does not affect the prothrombin index in any way and does not contribute to the formation of blood clots. If the drug is administered intravenously, the effect occurs within 10 minutes after the injection and lasts up to six to eight hours.

Indications for use

What are the pills for?

Etamzilat tablets are prescribed:

• with bleeding of various origins;
• with uterine bleeding;
• during menstruation;
• during surgical interventions;
• in dentistry, ophthalmology, urology, surgery and gynecology;
• with injuries and capillary bleeding;
• polymenorrhea;
• diabetic angiopathy;
• hemorrhagic diathesis.

Often the drug is prescribed for heavy periods, to reduce blood loss and prevent anemia.

Contraindications

• thrombosis;
• thromboembolism;
• hemorrhage while taking anticoagulants.

Side effects

• heaviness in the stomach;
• dizziness;
• heartburn;
• low blood pressure;
• headache.

Application instruction of Etamzilat (Way and dosage)

The dosage, route of administration and duration of treatment should be determined by the physician.

According to the instructions for Etamzilat tablets, the drug is administered orally at 0.25-0.5 g (one or two tablets), divided into 3 or 4 doses. For children, the daily dose is 10-15 mg per kg of body weight, divided into 3 doses.

Etamsylate sodium in solution for injection is used in the form of injections (intramuscularly, intravenously) retrobulbar or subconjunctival, depending on the indications.

The daily dose is 0.125-0.25 grams (for 3-4 applications), the maximum single dose is 0.75 g (parenterally - up to 0.375 g). External use is possible. A swab soaked in the preparation is applied to the wound.

The tool is also used in veterinary practice. The dosage for cats is 0.1 ml per kg of animal weight, injections are usually given twice a day.

Overdose

There are no data on cases of overdose.

Interaction

Do not mix in the same syringe with other drugs.

Terms of sale

A prescription in Latin or another language is required.

Storage conditions

In a dark place inaccessible to children, cool.

Best before date

Analogues

Etamzilat-KV, dicynone.

Etamzilat during pregnancy and lactation

During pregnancy, the drug is prescribed with caution. The medicine is contraindicated in the first trimester of pregnancy.

Reviews about Etamzilat

Reviews for tablets are good. The drug quickly and permanently stops bleeding. Especially often they are used for heavy discharge during menstruation.

Etamzilat price (where to buy)

The price of Etamzilat in tablets is about 104 rubles for 50 pieces.

Ampoules of Etamzilat sodium for injection (2 ml) cost about 84 rubles for 10 pieces.

Europharm* 4% discount with promo code medside11

Pharmacy IFK

PaniApteka

Reviews

Related videos

Etamzilat tablets description and instructions - CLOSE-UP *

Etamzilat Darnitsa

Reviews of the doctor about the drug Dicinon: indications, use, side effects, analogues

Etamzilat tablets - indications (video instruction) description, reviews

Hemostatic drugs for uterine bleeding: a list

Dicinon for menstruation: instructions, indications for use, reviews

Dicynon(etamsylate) and ferric chloride |||

Etamzilat KV

Ampoules without nail file

Hemostatic drugs for heavy periods: an overview of the best remedies

About it! can tell the color of the blood during menstruation!

How to stop bleeding during menstruation and in other cases Folk experience

One tablet of the drug contains sodium etamsylate 0.25 g and excipients.

Solution for injection contains etamzilate 0.125 per 1 ml + excipients (water for injection , sodium disulfite, disodium edetate, sodium sulfite anhydrous ).

Release form

Pills convex round, packs of 50 and 100 pieces.

Injection in ampoules, colorless, transparent or slightly yellow. Packs of 1, 2 or 10 ampoules.

pharmachologic effect

Angioprotector, hemostatic .

Pharmacodynamics and pharmacokinetics

The drug activates the formation thromboplastin And mucopolysaccharides , thus showing hemostatic activity .

Normalizes the rate of blood clotting, increases the stability and elasticity of the walls, improves processes microcirculation even in the smallest vessels and capillaries.

It is noteworthy that the drug does not affect prothrombin index and does not contribute to education. If the drug is administered intravenously, the effect occurs within 10 minutes after the injection and lasts up to six to eight hours.

Indications for use

What are the pills for?

Etamzilat tablets are prescribed:

• with different origin;
• at ;
• during menstruation;
• during surgical interventions;
• V dentistry, ophthalmology, urology, surgery And gynecology ;
• with injuries and capillary bleeding ;
• polymenorrhea ;
• diabetic angiopathy ;
• hemorrhagic diathesis.

Often the drug is prescribed for heavy periods, to reduce blood loss and prevent the occurrence anemia .

Contraindications

• thromboembolism ;
• hemorrhage against the background of the reception anticoagulants .

Side effects

• heaviness in the stomach;
• reduced;

Application instruction of Etamzilat (Way and dosage)

The dosage, route of administration and duration of treatment should be determined by the physician.

According to the instructions for Etamzilat tablets, the drug is administered orally at 0.25-0.5 g (one or two tablets), divided into 3 or 4 doses. For children, the daily dose is 10-15 mg per kg of body weight, divided into 3 doses.

Sodium etamsylate in solution for injections are used in the form of injections ( intramuscularly, intravenously ) retrobulbarno or subconjunctival , depending on the indications.

The daily dose is 0.125-0.25 grams (for 3-4 applications), the maximum single dose is 0.75 g (parenterally - up to 0.375 g). External use is possible. A swab soaked in the preparation is applied to the wound.

The tool is also used in veterinary practice. The dosage for cats is 0.1 ml per kg of animal weight, injections are usually given twice a day.

Overdose

There are no data on cases of overdose.

Interaction

Do not mix in the same syringe with other drugs.

Terms of sale

A prescription in Latin or another language is required.

Storage conditions

In a dark place inaccessible to children, cool.

Best before date

Analogues

Coincidence in the ATX code of the 4th level:

Etamzilat during pregnancy and lactation

During pregnancy, the drug is prescribed with caution. The medicine is contraindicated in the first trimester of pregnancy.

Reviews about Etamzilat

Reviews the tablets are good. The drug quickly and permanently stops bleeding. Especially often they are used for heavy discharge during menstruation.

Etamzilat price (where to buy)

Price Etamzilat tablets about 104 rubles for 50 pieces.

Ampoules of sodium etamsylate for injections (2 ml) cost about 84 rubles for 10 pieces.

• Internet pharmacies in Russia Russia
• Internet pharmacies of Ukraine Ukraine

ZdravCity

Etamzilat solution i/v and i/m 125mg/ml 2ml n10North China Pharm.Corporation Ltd.